Other frontotemporal neurocognitive disorder
Methodology & AI Transparency ⓘ
Other frontotemporal neurocognitive disorder Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Alzheimer, Dementia & Memory Health diagnostic criteria (G31.09), workup for Other frontotemporal neurocognitive disorder integrates targeted plasma/CSF biomarker in Other frontotemporal neurocognitive disorder (G31.09: evaluation when indicated) with evidence-graded therapy tailored to TSH & Fasting in Other frontotemporal neurocognitive disorder (G31.09: ApoB / HbA1c) response.
- 2 Real-world patient consensus: Federal ICD-10-CM code G31.09 categorizes Other frontotemporal neurocognitive disorder under Alzheimer, Dementia & Memory Health.
- 3 Typical cash cost range: Differential triage of Other frontotemporal neurocognitive disorder (G31.09) utilizes targeted plasma/CSF biomarker in Other frontotemporal neurocognitive disorder (G31.09: evaluation when indicated).
- 4 Top reported side effects / signs: Longitudinal Other frontotemporal neurocognitive disorder monitoring tracks TSH & Fasting in Other frontotemporal neurocognitive disorder (G31.09: ApoB / HbA1c) toward Optimal cardiometabolic neuroprotection (G31.09).
Ask our AI Specialists anything about Other frontotemporal neurocognitive disorder
What Is Other frontotemporal neurocognitive disorder?
Under Alzheimer, Dementia & Memory Health diagnostic criteria (G31.09), workup for Other frontotemporal neurocognitive disorder integrates targeted plasma/CSF biomarker in Other frontotemporal neurocognitive disorder (G31.09: evaluation when indicated) with evidence-graded therapy tailored to TSH & Fasting in Other frontotemporal neurocognitive disorder (G31.09: ApoB / HbA1c) response.
Pathophysiology, Underlying Causes & Clinical Presentation
In Other frontotemporal neurocognitive disorder (G31.09), physiological disruption stems from phosphorylated tau proteinopathy [Other frontotemporal neurocognitive disorder G31.09], informing Alzheimer, Dementia & Memory Health protocols that track MoCA Cognitive Screening in Other frontotemporal neurocognitive disorder (G31.09: Score) (>= 26 / 30 (G31.09)).
Common Symptoms & Clinical Signs
- • Presentation of Other frontotemporal neurocognitive disorder (G31.09): short-term recall difficulty in Other frontotemporal neurocognitive disorder (G31.09: for recent conversations,)
- • Secondary Other frontotemporal neurocognitive disorder clinical sign: word-finding pauses, difficulty in Other frontotemporal neurocognitive disorder (G31.09: managing multi-step finances,)
- • Symptom flares in Other frontotemporal neurocognitive disorder correlating with TSH & Fasting in Other frontotemporal neurocognitive disorder (G31.09: ApoB / HbA1c) deviation outside Optimal cardiometabolic neuroprotection (G31.09)
- • Functional memory & cognition impact requiring targeted plasma/CSF biomarker in Other frontotemporal neurocognitive disorder (G31.09: evaluation when indicated) evaluation (G31.09)
Other frontotemporal neurocognitive disorder Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G31.09 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Alzheimer, Dementia & Memory Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: TSH & Fasting in Other frontotemporal neurocognitive disorder (G31.09: ApoB / HbA1c) | Optimal cardiometabolic neuroprotection (G31.09) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: MoCA Cognitive Screening in Other frontotemporal neurocognitive disorder (G31.09: Score) | >= 26 / 30 (G31.09) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Homocysteine & Vitamin in Other frontotemporal neurocognitive disorder (G31.09: B12) | Homocysteine < 9 umol/L; B12 > 500 pg/mL (G31.09) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Other frontotemporal neurocognitive disorder
Treatment selection for Other frontotemporal neurocognitive disorder depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Other frontotemporal neurocognitive disorder)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Valsartan vs. other angiotensin II receptor blockers in the treatment of high: What a 13,110-Participant Study Found Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure. International journal of clinical practice • 2009-05-15 • Meta-Analysis | N = 13,110 | 99/100 | PMID 19392925 ↗ |
| New Insights on Efficacy comparison of monotherapies and combination therapies for androgenetic: What a 3,133-Participant Study Found In recent years, combination therapies are showing significant promise as potential therapies. Dermatologic therapy • 2022-03-15 • Meta-Analysis | N = 3,133 | 99/100 | PMID 34897933 ↗ |
| New Insights on Combination Therapy in Androgenetic hair loss: A Network Meta-Analysis of: What a 3,012-Participant Study Found Based on the current studies, we found that the combination of Minoxidil with spironolactone, PRPF, flutamide, and finasteride may offer better treatment outcomes for patients with androgenetic hair loss. Aesthetic plastic surgery • 2026-07-15 • Meta-Analysis | N = 3,012 | 99/100 | PMID 42168420 ↗ |
| New Insights on Safety profile of telmisartan as single-drug treatment or combined with: What a 8,023-Participant Study Found The consolidated data show that telmisartan +/- HCTZ are well tolerated in patients of all ages and have placebo-like tolerabilities. Blood pressure. Supplement • 2008-06-15 • Randomized Controlled Trial | N = 8,023 | 96/100 | PMID 18705533 ↗ |
| New Insights on Telmisartan and amlodipine single-pill combinations vs amlodipine single-drug: What a 1,097-Participant Study Found Superior BP reductions were also seen with T40-T80/A5 vs A10, with BP goal rates at least as high as with A10; however, there was significantly more peripheral edema with A10 (27.2% vs 4.3% for pooled. Journal of clinical hypertension (Greenwich, Conn.) • 2011-07-15 • Randomized Controlled Trial | N = 1,097 | 96/100 | PMID 21762357 ↗ |
Other frontotemporal neurocognitive disorder Patient Community & “People Like Me” Threads
Filter Other frontotemporal neurocognitive disorder community threads and patient logs by age, biological sex, dosage, and treatment duration.